Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of ambient air pollution with cognitive functioning and markers of structural brain damage: The Maastricht study.

Environment international·2024
Same author

A global initiative to deliver precision health in diabetes.

Nature medicine·2024
Same author

Optimising personal continuity for older patients in general practice: a cluster randomised stepped wedge pragmatic trial.

BMJ open·2024
Same author

Accelerometer-derived physical activity and sedentary time and cardiac biomarkers: The Maastricht Study.

Frontiers in cardiovascular medicine·2023
Same author

Cognitive Functioning in Survivors of Hematopoietic Stem Cell Transplantation Compared With a Matched General Population Sample-The Maastricht Observational Study of Late Effects After Stem Cell trAnsplantation Study.

Transplantation and cellular therapy·2023
Same author

In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: A 20-year follow-up in the CARRÉ cohort study.

Seminars in arthritis and rheumatism·2022

Related Experiment Video

Updated: Jul 14, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

[Guideline 'Cardiovascular Risk Management'].

J S Burgers1, M L Simoons, A W Hoes

  • 1Kwaliteitsinstituut voor de Gezondheidszorg CBO, Postbus 20.064, 3502 LB Utrecht. j.burgers@cbo.nl

Nederlands Tijdschrift Voor Geneeskunde
|June 8, 2007
PubMed
Summary

This guideline provides an integrated approach to managing cardiovascular disease (CVD) risk factors. It outlines risk assessment and treatment strategies, including lifestyle counseling and pharmacotherapy, for high-risk individuals to prevent future cardiovascular events.

Related Experiment Videos

Last Updated: Jul 14, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Public Health

Context:

  • Atherothrombosis significantly contributes to cardiovascular disease (CVD) burden.
  • Effective management of modifiable risk factors is crucial for CVD prevention.
  • Clinical guidelines are essential for standardizing evidence-based cardiovascular risk management.

Purpose:

  • To provide an integral approach to managing all relevant risk factors for CVD caused by atherothrombosis.
  • To establish criteria for assessing CVD risk factors in various patient populations.
  • To guide therapeutic interventions, including lifestyle counseling and pharmacotherapy, for high-risk individuals.

Summary:

  • The guideline targets patients with existing CVD, diabetes mellitus type 2 (DM2), hypertension, hypercholesterolemia, and specific demographic groups (e.g., older smokers).
  • Assessment of CVD risk factors is recommended for eligible individuals, with lifestyle counseling for all high-risk patients.
  • Pharmacological recommendations include acetylsalicylic acid, beta-blockers, ACE inhibitors, and statins based on specific criteria (e.g., LDL-cholesterol levels).
  • For patients with DM2, statins, blood pressure-lowering drugs, and glucose-lowering drugs are recommended under specific conditions.
  • In patients without CVD and DM2, treatment is initiated if the estimated 10-year CVD mortality risk exceeds 10%.

Impact:

  • Facilitates personalized treatment and follow-up plans based on individual risk profiles, comorbidities, and patient preferences.
  • Aims to reduce the incidence and mortality associated with cardiovascular diseases.
  • Promotes a proactive and comprehensive strategy for cardiovascular risk management in clinical practice.